Your SlideShare is downloading. ×
0
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Teva is acquirering cephalon
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Teva is acquirering cephalon

1,208

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,208
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. TEVA isacquiringCEPHALON 02/05/2010
  • 2. Teva profile
    • Israeli company
    • 3. 40 000 employees worldwide
    • 4. 1st generic company.
    • 5. Teva also develops branded drug activity with its multiple sclerosis treatment Copaxone3,3 $B (2010)…
  • Teva profile (product sales)
    With current 16,1 $B annual sales, Teva has showed impressive growth late 10 years thanks to important M&A.
  • 6. Teva profile (Product sales)
    MS drug Copaxone is taking a growing part in Tevapharmaceutical business (20% in 2008)
  • 7. Cephalon profile
    • American company
    • 8. 4 000 employees worldwide
    • 9. 2 key TA: Oncology and Antialgic.
    • 10. Current key TO Chephalon narcolepsy treatment Provigil will lose patent April 2012.
  • Whatis the point ?
    • “This is transforming for Teva’s branded business, as it will help us to deliver on our strategic goal of creating a diversified, multi-faceted company,” said Teva Chief Executive ShlomoYanai.
    • 11. ….
    • 12. TEVA which doesn’t want to be generic company exclusively ,will benefit of an existing branded drugs portfolio from Cephalon (20) as well as will integrate 20 to 30 drugs in phase 2/3 development stage.
    • 13. This should provide additional TO to TEVA for the next few years.
    Link to more detailed Cephalon pipeline presentation
  • 14. The agreement
    • In march 2011 the canadianValeantlaunched a hostile Cephalonbid of 5.7 $B (73 $ per share, +29% on regularCephalon value share).
    • 15. TEVA offered a non-hostile 12% up bid for Cephalon, at 81,5 $ a share.
  • Furtherreading
    • Linksforpharmarecomends the following resources:
    • 16. http://www.bnet.com/blog/drug-business/can-cephalon-a-company-in-mourning-fend-off-the-hostile-borg-at-valeant/7855?tag=content;drawer-container
  • Presentationsfromlinksforpharma
    • Linksforpharma.com is a pharmaceutical industry dedicated portal.
    • 17. Linksforpharma.com provides a selection of resources from the internet on the pharma sector.
    • 18. Registered people at Linksforpharma may publish individual profile as well as company profile to built a sectorial community.
    • 19. As a free service, linksforpharma.com creates and publishes presentations, illustrating news and development in the pharma field.
    • 20. Presentations from linksforpharma (of which this one), have been made thanks to internet publicly available information, such as: articles, blog posts, press releases, yahoo finance, google news, etc…

×